Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

220.05 -0.05 (-0.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality ↗

June 23, 2025

The midstage study hit all its goals, representing a "best case" scenario, according to one analyst.

Via Investor's Business Daily

Why Is Cidara Therapeutics Stock Trading Higher On Monday? ↗

June 23, 2025

Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.

Via Benzinga

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results ↗

June 23, 2025

Via Benzinga

Topics Stocks

These stocks are gapping in today's session ↗

June 23, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Why Cidara Therapeutics (CDTX) Stock Is Falling ↗

April 22, 2024

Cidara Therapeutics shares are trading lower by 24.4% Monday afternoon. The company announced a 1-for-20 reverse stock split.

Via Benzinga

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

April 16, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 21, 2024

Via Benzinga

Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗

November 14, 2024

CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage...

Via Talk Markets

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 08, 2024

Via Benzinga

CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

May 16, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

May 16, 2024

WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara...

Via TheNewswire.com

Topics Regulatory Compliance

CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 15, 2024

CDTX stock results show that Cidara Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX

May 14, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

May 13, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

May 13, 2024

WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara...

Via TheNewswire.com

Topics Regulatory Compliance

CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm

April 25, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX

April 25, 2024

From The Rosen Law Firm, P.A.

Via Business Wire

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 25, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 25, 2024

Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!

Via InvestorPlace

Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗

April 25, 2024

Via Benzinga

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 23, 2024

Via Benzinga

Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

April 23, 2024

Via Benzinga

CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

April 22, 2024

CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 30, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 25, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.